Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: An investigation based on pharmacokinetic modeling

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 3, 2010, Pages 279-287

  Kletting, Peter ^a   Meyer, Christoph ^a   Reske, Sven N ^a   Glatting, Gerhard ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

anti CD20 antibody; pharmacokinetic modeling; preload; radioimmunotherapy

Indexed keywords

CD20 ANTIBODY; CD20 ANTIBODY IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG DISTRIBUTION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SIMULATION; SPLEEN SIZE; TUMOR VOLUME;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; COMPUTER SIMULATION; HUMANS; INDIVIDUALIZED MEDICINE; LYMPHOMA, B-CELL; MODELS, BIOLOGICAL; RADIOIMMUNOTHERAPY; SPLEEN; TUMOR BURDEN;

EID: 77954913109     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0746     Document Type: Article

References (31)

1. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008; 359:613.
2. Knox S, Goris M, Trisler K, et al. Yttrium-90-labeled anti- CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457.
3. Glatting G, Muller M, Koop B, et al. Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia. J Nucl Med 2006;47: 1335.
4. Sgouros G. Update: Molecular radiotherapy: Survey and current status. Cancer Biother Radiopharm 2008;23: 531.
5. Kletting P, Bunjes D, Reske SN, et al. Improving anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model. J Nucl Med 2009;50:296.
6. Sharkey RM, Press OW, Goldenberg DM. A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: Prospects for dual-targeted antibody/radio- antibody therapy. Blood 2009;113:3891.
7. Gopal AK, Press OW, Wilbur SM, et al. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 2008;112:830.
8. Sharkey RM, Karacay H, Johnson CR, et al. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non- Hodgkin lymphoma. J Nucl Med 2009;50:444.
9. Kletting P, Kull T, Bunjes D, et al. Radioimmunotherapy with anti-CD66 antibody: Improving the biodistribution using a physiologically based pharmacokinetic model. J Nucl Med 2010;51:484.
10. Eger RR, Covell DG, Carrasquillo JA, et al. Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans. Cancer Res 1987;47:3328.
11. Schmid J, Moller P, Moldenhauer G, et al. Monoclonal antibody uptake in B-cell lymphomas: Experimental studies in nude mouse xenografts. Cancer Immunol Immunother 1993;36:274.
12. Dhingra S, Freedenberg M, Quo CF, et al. Computational modeling of a metabolic pathway in ceramide de novo synthesis. Proceedings of the 29th Annual International Conference of the IEEE EMBS Cite Internationale, Lyon, France, August 23-26, 2007;1405.
13. Westermann J, Pabst R. Distribution of lymphocyte subsets and natural killer cells in the human body. Clin Investig 1992;70:539.
14. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987;6:559.
15. Matthews DC. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995;85:1122.
16. Matthews DC, Badger CC, Fisher DR, et al. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody. Cancer Res 1992;52:1228.
17. Ng CM, Bruno R, Combs D, et al. Population pharmacoki- netics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005;45:792.
18. Bikoue A, George F, Poncelet P, et al. Quantitative analysis of leukocyte membrane antigen expression: Normal adult values. Cytometry 1996;26:137.
19. Thomas GD, Chappell MJ, Dykes PW, et al. Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: A biomathematical model. Cancer Res 1989;49:3290.
20. Curti BD, Urba WJ, Alvord WG, et al. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: Changes during treatment. Cancer Res 1993;53: 2204.
21. Ferl GZ, Wu AM, DiStefano JJ 3rd. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng 2005; 33:1640.
22. Kaufman EN, Jain RK. Effect of bivalent interaction upon apparent antibody affinity: Experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res 1992;52:4157.
23. Kletting P, Kull T, Bunjes D, et al. Radioimmunotherapy with anti-CD66 antibody: Improving the biodistribution using a physiologically based pharmacokinetic model. J Nucl Med 2010;51:484.
24. Kletting P, Bunjes D, Reske SN, et al. Improving anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model. J Nucl Med 2009;50:296.
25. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987;6:559.
26. Baxter LT, Zhu H, Mackensen DG, et al. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 1994;54:1517.
27. Johnstone RW, Andrew SM, Hogarth MP, et al. The effect of temperature on the binding kinetics and equilibrium constants of monoclonal antibodies to cell surface antigens. Mol Immunol 1990;27:327.
28. Knox S, Goris M, Trisler K, et al. Yttrium-90-labeled anti- CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457.
29. Baxter LT, Zhu H, Mackensen DG, et al. Biodistribution of monoclonal antibodies: Scale-up mouse to human using a physiologically based pharmacokinetic model. Cancer Res 1995;55:4611.
30. Bikoue A, George F, Poncelet P, et al. Quantitative analysis of leukocyte membrane antigen expression: Normal adult values. Cytometry 1996;26:137.
31. Eger RR, Covell DG, Carrasquillo JA, et al. Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans. Cancer Res 1987;47:3328.